Drugs / R21
R21
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06958198 | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT06507605 | Aug 2024 → Jan 2026 | malaria | Serum Institute of India Pvt. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06320535 | Mar 2024 → Jun 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05357560 | Jul 2023 → Dec 2025 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03970993 | Jun 2019 → Aug 2021 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT03896724 | May 2019 → Jul 2023 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT03580824 | Apr 2019 → Jun 2022 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07183371 | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07147400 | Aug 2025 → Nov 2027 expected | malaria | Serum Institute of India Pvt. Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06578572 | May → Dec 2024 overdue | malaria | London School of Hygiene and Tropical Medicine | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02600975 Comparator | Dec 2015 → Jan 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02572388 Comparator | Oct 2015 → Aug 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02925403 Comparator | Aug 2016 → Feb 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/2 | NCT02905019 Comparator | Aug 2016 → Dec 2017 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06080243 Comparator | Mar 2025 → Sep 2027 expected | — | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07194668 Comparator | Apr → Dec 2026 expected | Plasmodium falciparum malaria, vaccinia | University of Oxford | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03580824 ↗ |
| Known as | R21 Malaria Vaccine (Recombinant) | “R21 Malaria Vaccine (Recombinant) For Bedside Mixing” NCT07147400 ↗ |
| Known as | R21/Matrix-M | “Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up” PMID 38813551 ↗ Oct 2023 |
| Known as | R21/MM | “Adjuvanted R21(R21/MM) in Adults, Young Children and Infants in Kilifi, Kenya” NCT03580824 ↗ |
| Modality | Vaccine | “R21 is a malaria vaccine comprising nanoparticles” PMID 39805302 ↗ Jan 2025 |
| Route | Intramuscular | “All vaccinations will be administered intramuscularly.” NCT02600975 ↗ |